Danish drugmaker Novo Nordisk (NVO) announced that introductory doses of blockbuster weight loss drugs Wegovy and Ozempic will be available for U.S. cash-pay price of $199 a month, which is 30% less than the current self-pay price and matches Eli Lilly’s (LLY) price for a low dose of its obesity shot Zepbound and is less than the price of higher doses, reported Bloomberg’s Naomi Kresge and Madison Muller.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Tiger Global buys Netflix, exits Eli Lilly in Q3
- Mixed options sentiment in Novo Nordisk with shares down 1.65%
- Novo Nordisk price target lowered to DKK 400 from DKK 425 at Berenberg
- Novo Nordisk (NVO) Gets New Chair — Can It Catch Up with Rival Eli Lilly in Obesity Market?
- Novo Nordisk Announces New Board Leadership Following Extraordinary Meeting